OPEN

Author Correction: Neuroprotective effects of low-dose G-CSF plus meloxicam in a rat model of anterior ischemic optic neuropathy

Pei-Kang Liu, Yao-Tseng Wen, Wei Lin, Kishan Kapupara, Minghong Tai & Rong-Kung Tsai

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-020-66977-9>, published online 25 June 2020

The original version of this Article contained an error in Figure 4 where the number of TUNEL-positive cells in Figure 4A did not match the number of cells in Figure 4B. The original Figure 4 and accompanying legend appear below.

The original Article has been corrected.

Published online: 14 September 2021

Figure 4. Analysis of RGC apoptosis in the RGC layer through TUNEL assay at four weeks after rAION induction. **(A)** Representative images of double-stained apoptotic cells in the RGC layers in each group. The apoptotic cells (TUNEL-positive cells) in green were stained with TUNEL staining, and the nuclei of the RGCs in blue were labeled with DAPI staining. **(B)** Quantification of TUNEL-positive cells per high-power field. Data are expressed as mean $\pm$ SD for each group ($n=6$). Treatment with low-dose G-CSF plus meloxicam significantly reduced the number of apoptotic RGC by 3.6- and 2.5-fold compared with the meloxicam-treated and low-dose G-CSF-treated groups, respectively. $*p < 0.05$.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021